Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BeiGene Ltd ( (HK:6160) ) has issued an update.
BeOne Medicines Ltd., formerly known as BeiGene, Ltd., has announced its official continuation as a Swiss stock corporation, effective May 27, 2025. This transition includes the adoption of new Swiss Articles, the appointment of Ernst & Young AG as the Swiss statutory auditor, and a change in the company’s English name and website. The move signifies a strategic shift in the company’s operational base and corporate identity, potentially impacting its market positioning and stakeholder engagement.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,789,106
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$236.3B
See more data about 6160 stock on TipRanks’ Stock Analysis page.